NCI Grants Lysin Exclusive Rights to Mesothelin Cancer Immunotoxins
Published Date: 9/10/2025
Notice
Summary
The National Cancer Institute is planning to give Lysin Therapeutics an exclusive license to use their special anti-mesothelin immunotoxins to treat cancers that have mesothelin. This means Lysin can develop and sell new cancer treatments, potentially helping patients with tough-to-treat tumors. The deal could speed up new medicines and impact cancer care soon, with business and health benefits on the horizon.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
NCI plans exclusive license to Lysin
The National Cancer Institute (NCI) is contemplating granting an NCI Exclusive Patent License to Lysin Therapeutics, Inc., a company located in Silver Spring, MD, to practice inventions embodied in the patents listed in the notice's Supplementary Information. This gives Lysin the legal right to develop and commercialize the patented anti-mesothelin immunotoxin inventions listed in that supplement.
Potential new treatments for mesothelin cancers
The license under consideration covers anti-mesothelin immunotoxins for treating mesothelin-expressing cancers. If granted, the license would allow Lysin Therapeutics to develop and sell treatments that use these patented anti-mesothelin immunotoxins for cancers that express mesothelin.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in